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ABSTRACT
Background: Heart failure with preserved ejection
fraction (HFpEF) causes significant cardiovascular
morbidity and mortality. Current consensus guidelines
reflect the neutral results from randomised controlled
trials (RCTs). Adequate trial reporting is a
fundamental requirement before concluding on RCT
intervention efficacy and is necessary for accurate
meta-analysis and to provide insight into future trial
design. The Consolidated Standards of Reporting
Trials (CONSORT) 2010 statement provides a
framework for complete trial reporting. Reporting
quality of HFpEF RCTs has not been previously
assessed, and this represents an important validation
of reporting qualities to date.
Objectives: The aim was to systematically identify
RCTs investigating the efficacy of pharmacological
therapies in HFpEF and to assess the quality of
reporting using the CONSORT 2010 statement.
Methods: MEDLINE, EMBASE and CENTRAL
databases were searched from January 1996 to
November 2015, with RCTs assessing
pharmacological therapies on clinical outcomes
in HFpEF patients included. The quality of
reporting was assessed against the CONSORT 2010
checklist.
Results: A total of 33 RCTs were included. The
mean CONSORT score was 55.4% (SD 17.2%).
The CONSORT score was strongly correlated with
journal impact factor (r=0.53, p=0.003) and
publication year (r=0.50, p=0.003). Articles
published after the introduction of CONSORT 2010
statement had a significantly higher mean score
compared with those published before (64% vs
50%, p=0.02).
Conclusions: Although the CONSORT score has
increased with time, a significant proportion of HFpEF
RCTs showed inadequate reporting standards. The level
of adherence to CONSORT criteria could have an
impact on the validity of trials and hence the
interpretation of intervention efficacy. We recommend
improving compliance with the CONSORT statement
for future RCTs.
INTRODUCTION
Randomised controlled trials (RCTs) along
with meta-analysis provide the highest level of
evidence on the efﬁcacy of healthcare inter-
ventions. Accurate interpretation of results
and critical appraisal of RCTs depends on
adequate reporting and a study design that is
free from bias. Studies have shown poor
reporting standards in RCTs,1 particularly so
in areas concerning trial methodology.2 3 The
Consolidated Standards of Reporting Trials
KEY QUESTIONS
What is already known about this subject?
▸ Several studies have shown that a significant
proportion of randomised controlled trials
(RCTs) demonstrate poor reporting standards
despite the availability of the Consolidated
Standards of Reporting Trials (CONSORT) state-
ment. Heart failure with preserved ejection frac-
tion (HFpEF) is a considerable source of
morbidity and mortality, with no known disease-
modifying treatments. The role of reporting of
HFpEF trial findings has not been assessed, and
the size of the problem is not known.
What does this study add?
▸ We present the first systematic assessment of
reporting standards for RCTs investigating
therapies for HFpEF using CONSORT, and iden-
tify trends and areas which authors, reviewers
and journal editorial boards can target for
improvement.
How might this impact on clinical practice?
▸ Improvements in trial reporting and provision of
relevant information for HFpEF will allow import-
ant post hoc analysis of trial findings and guide
future trial design. This will provide a greater
understanding of HFpEF heterogeneity and help
to identify phenotypes with tailored therapies.
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(CONSORT) statement,4 updated in 2010, aims to
improve the quality of reporting clinical trials, allowing
results to be better interpreted and critically appraised.
Heart failure with preserved left ventricular ejection
fraction (HFpEF) is a major cause of morbidity and mor-
tality, comparable to heart failure with reduced left ven-
tricular ejection fraction (HFrEF). HFpEF is the cause of
symptomatic heart failure in over half of cases, with
increasing prevalence in an increasingly ageing popula-
tion.5 The recently published European Society of
Cardiology heart failure guidelines reﬂect the absence
of disease-modifying effects demonstrated in HFpEF
RCTs and meta-analyses.6–10
The absence of evidence for HFpEF treatment efﬁcacy
may be due to differing pathophysiological processes
compared with that for HFrEF, difﬁculty in clinical diag-
nosis and heterogeneity of included study populations
with subgroup phenotypes. In addition to these well-
recognised issues, clear reporting of HFpEF trials is a
fundamental requirement to assess the appraisal of
methodological approaches and validity of results, as
well as for the accuracy of meta-analysis and subgroup
analysis. Adequate reporting of information speciﬁcally
relevant to issues in the HFpEF trial design will also help
direct future clinical trial design to optimise effective-
ness. Trends in the quality of HFpEF trial reporting and
areas for improvement that will be of clinical and
research beneﬁt have not previously been reported.
The aim of this study was to systematically identify
RCTs investigating the efﬁcacy of pharmacological ther-
apies in HFpEF published between 1996 and 2015, to
assess quality of reporting using the CONSORT 2010
statement and also to identify temporal trends.
METHODS
This article has been reported in accordance with the
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses.11
Search strategy
We systematically searched MEDLINE, EMBASE and
CENTRAL databases for all clinical trials using the key-
words: heart failure and normal ejection fraction, heart
failure and preserved cardiac function, heart failure and
preserved ejection fraction, diastolic heart failure, diastolic
dysfunction, HFpEF and HFnEF (see online supplemen-
tary material table S1 for full search protocol). Results
were ﬁltered for RCTs using predesigned and validated
ﬁlters. The search was run on 20 November 2015, with
results included from 1 January 1996 to 20 November
2015. The reference lists of included studies and relevant
systematic reviews were searched for additional studies. No
published study protocol exists for this systematic review.
Inclusion and exclusion criteria
Inclusion criteria were: (1) RCT, (2) trial inclusion cri-
teria specifying heart failure signs and symptoms with
left ventricular ejection fraction (LVEF) ≥40%, (3)
pharmacological intervention with placebo or pharma-
cological comparison and (4) outcomes including all-
cause and cardiovascular mortality, hospitalisation and
changes in New York Heart Association functional class
(NYHA), exercise capacity (6-min walking distance, VO2
max) or quality of life (measured using the Minnesota
Living with Heart Failure Questionnaire).
Exclusion criteria were: (1) treatment of acute heart
failure, (2) treatment duration <7 days, (3) studies using
healthy controls, (4) non-English language publications,
(5) abstracts and conference publications and (6)
unpublished studies.
Study selection
After the removal of duplicates, the title and abstracts of
initial search results were screened for relevance. The
full texts of remaining results were independently
assessed by three authors (SLZ, FTC, EM) for inclusion
based on predetermined inclusion and exclusion cri-
teria. The ﬁnal list of included studies was decided by
discussion between authors and required full agreement.
Remaining disagreements were resolved by AAN.
Assessment of quality
Reporting quality was assessed using the CONSORT
2010 score (table 1). Each item on the checklist was
answered ‘Yes’, ‘No’ or ‘Not Applicable (NA)’, with each
‘Yes’ scoring 1 point. Each item was weighted equally. An
overall reporting quality score percentage was calculated
for each study by dividing the number of points by the
total available (excluding NA). Two independent phys-
ician reviewers (SLZ and FTC) assessed the quality of
reporting. Discrepancies in scoring were resolved with
discussion between the two reviewers. Any unresolved
discrepancies were decided by a third reviewer (EM).
Statistical analysis
Interobserver analysis scores were assessed for correl-
ation using Cohen’s κ score. Pearson’s product–moment
correlation was used to assess the correlation between
CONSORT score and prespeciﬁed variables ( journal
impact factor, journal 5-year impact factor, article inﬂu-
ence, eigenfactor, year of publication, author number,
participant number and trial length). Mann-Whitney
U test was used to test for binary non-parametric data.
Journal metrics were obtained from InCites Journal
Citation Reports.12 Risk of bias for each study was not
analysed. Statistical analysis was carried out using IBM
SPSS Statistics V.22 and Microsoft Excel 2011.
RESULTS
Study search results and interobserver variability
Initial search identiﬁed 3561 potential studies
(MEDLINE n=1128, EMBASE n=1442, CENTRAL
n=991). After the removal of duplicates and non-
relevant articles, the full texts of 172 articles were
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Table 1 CONSORT 2010 Checklist and percentage of articles that adequately report each CONSORT 2010 checklist item
Title and abstract
1a Identification as a randomised trial in the title 30.3% (23/33)
1b Structured summary of trial design, methods, results and conclusions (for specific guidance,
see CONSORT for abstracts)
9.1% (3/33)
Introduction
Background and objectives
2a Scientific background and explanation of rationale 93.9% (31/33)
2b Specific objectives or hypotheses 87.9% (29/33)
Methods
Trial design
3a Description of trial design (such as parallel, factorial) including allocation ratio 42.4% (14/33)
3b Important changes to methods after trial commencement (such as eligibility criteria),
with reasons
100% (6/6)
Participants
4a Eligibility criteria for participants 97% (32/33)
4b Settings and locations where the data were collected 21.2% (7/33)
Interventions
5 The interventions for each group with sufficient details to allow replication, including how
and when they were actually administered
78.8% (26/33)
Outcomes
6a Completely defined prespecified primary and secondary outcome measures, including how
and when they were assessed
66.7% (22/33)
6b Any changes to trial outcomes after the trial commenced, with reasons NA (0/0)*
Sample size
7a How sample size was determined 69.7% (23/33)
7b When applicable, explanation of any interim analyses and stopping guidelines 100% (4/4)
Randomisation
Sequence generation
8a Method used to generate the random allocation sequence 33.3% (11/33)
8b Type of randomisation; details of any restriction (such as blocking and block size) 33.3% (11/33)
Allocation concealment mechanism
9 Mechanism used to implement the random allocation sequence (such as sequentially
numbered containers), describing any steps taken to conceal the sequence until
interventions were assigned
12.1% (4/33)
Implementation
10 Who generated the random allocation sequence, who enrolled participants, and who
assigned participants to interventions
21.2% (7/33)
Blinding
11a If done, who was blinded after assignment to interventions (for example, participants,
care providers, those assessing outcomes) and how
32.3% (10/31)
11b If relevant, description of the similarity of interventions 34.5% (10/29)
Statistical methods
12a Statistical methods used to compare groups for primary and secondary outcomes 97.0% (32/33)
12b Methods for additional analyses, such as subgroup analyses and adjusted analyses 77.8% (14/18)
Results
Participant flow
13a For each group, the numbers of participants who were randomly assigned, received intended
treatment, and were analysed for the primary outcome
66.7% (22/33)
13b For each group, losses and exclusions after randomisation, together with reasons 65.6% (21/32)
Recruitment
14a Dates defining the periods of recruitment and follow-up 45.5% (15/33)
14b Why the trial ended or was stopped 12.1% (4/33)
Baseline data
15 A table showing baseline demographic and clinical characteristics for each group 90.9% (30/33)
Numbers analysed
16 For each group, number of participants (denominator) included in each analysis and whether
the analysis was by original assigned groups
54.5% (18/33)
Outcomes and estimation
17a For each primary and secondary outcome, results for each group, and the estimated effect
size and its precision (such as 95% confidence interval)
39.4% (13/33)
Continued
Zheng SL, Chan FT, Maclean E, et al. Open Heart 2016;3:e000449. doi:10.1136/openhrt-2016-000449 3
Heart failure and cardiomyopathies
group.bmj.com on September 27, 2016 - Published by http://openheart.bmj.com/Downloaded from 
reviewed (ﬁgure 1). The reference list of included arti-
cles and systematic review articles was searched for add-
itional trials, identifying one other study. In total, 33
studies were included for analysis (see online supple-
mentary material table S2 for study summary). Cohen’s
κ score for interobserver variability of CONSORT check-
list scoring was 0.86 (91.3% observed agreement, 1115
of 1221 items).
Reporting quality
The mean article CONSORT score was 55.4% (range
23.3–93.8%, SD 17.2%; ﬁgure 2 and table 1). No article
scored 100%. The best reported criteria were: protocol
(item 24, 100%, 13/13), changes to methodology (item
3b, 100%, 6/6), interim analysis (item 7b, 100%, 4/4),
interpretation (item 22, 97%, 32/33), eligibility criteria
(item 4a, 97%, 32/33), statistical methods (item 12a,
97.0%, 32/33), background (item 21, 93.9%, 31/33) and
baseline data (item 15, 90.9%, 30/33; ﬁgure 2 and
table 1). The worst reported criteria were presentation of
binary outcomes (item 17b, 0%, 0/7), abstract (item 1b,
9.1%, 3/33), trial termination (item 14b, 12.1% 4/33)
and allocation concealment (item 9, 12.1%, 4/33).
Time trend and CONSORT statement updates
The CONSORT 2010 score increased with time and
showed strong correlation with the year of publication
(r=0.50, p=0.003; ﬁgure 3). Articles published after the
CONSORT 1996 statement but before the CONSORT
2001 update had a mean score of 41.0% (SD 3.3%;
ﬁgure 4). Articles published between CONSORT 2001
Table 1 Continued
17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended 0.0% (0/7)
Ancillary analyses
18 Results of any other analyses performed, including subgroup analyses and adjusted
analyses, distinguishing prespecified from exploratory
68.8% (11/16)
Harms
19 All important harms or unintended effects in each group (for specific guidance, see
CONSORT for harms)
53.1% (17/32)
Discussion
Limitations
20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant,
multiplicity of analyses
78.8% (26/33)
Generalisability
21 Generalisability (external validity, applicability) of the trial findings 87.9% (29/33)
Interpretation
22 Interpretation consistent with results, balancing benefits and harms, and considering other
relevant evidence
97.0% (32/33)
Other information
Registration
23 Registration number and name of trial registry 48.5% (16/33)
Protocol
24 Where the full trial protocol can be accessed, if available 100.0% (13/13)
Funding
25 Sources of funding and other support (such as supply of drugs), role of funders 36.4% (12/33)
Figure 1 Flow chart of study search, selection, inclusion and
exclusion of articles.
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and CONSORT 2010 had a mean score of 50.2% (SD
14.5%). Articles published after CONSORT 2010 had a
mean score of 63.8% (SD 18.1%). There was a signiﬁcant
increase in the mean score of articles published after
CONSORT 2010 compared with those published between
CONSORT 2001 and 2010 (difference between means
13.6%, p=0.02), whereas the difference between
CONSORT 1996 and 2010 scores approached signiﬁcance
(difference between means 22.8%, p=0.07). There was no
signiﬁcant difference between CONSORT 1996 and 2001
scores (difference between means 9.2%, p=0.53).
Correlation with journal impact factor
The CONSORT score was strongly correlated with
journal impact factor (r=0.53, p=0.003) and journal
5-year impact factor (r=0.49, p=0.006). The score was
also strongly correlated with article inﬂuence score
(r=0.50, p=0.005) and with eigenfactor score (r=0.36,
p=0.05).
Correlation with other variables
The CONSORT score was strongly correlated with
author number (r=0.52, p=0.002) but not with partici-
pant number (r=0.30, p=0.09) or treatment duration
(r=0.17, p=0.34). Trials that included ≥100 patients had
a higher CONSORT score (63.7% vs. 46.5%, p=0.011).
There was no signiﬁcant difference for treatment dur-
ation (≥12 m or <12 m), trial assignment (parallel or
crossover) or funding sponsor (national/charity/aca-
demic or pharmaceutical company/industry; table 2).
Reporting quality of Methods and Results
The mean reporting score for the Methods section (check-
list items 3a–12b) was 51.9% (range 15.4–92.9%, SD
Figure 2 Percentage of studies adequately reporting each CONSORT 2010 checklist item where applicable.
Figure 3 The year of publication
and CONSORT 2010 score.
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19.7%) and that for the Results section (checklist items
13a–19) was 51.9% (range 12.5–100%, SD 24.1%). There
remained correlation with the year of publication and jour-
nal’s impact factor (Methods: r=0.32 and r=0.36; Results:
r=0.39 and r=0.51; combined methods and results: r=0.38
and r=0.47), which was not signiﬁcantly different from cor-
relation coefﬁcient of total score with the year of
publication (p>0.20 for all). Mean scores for Methods and
Results increased after CONSORT 2010 publication from
42.5% to 61.9% and 44.1% to 59.3%, respectively.
DISCUSSION
In this study, we have systematically identiﬁed all RCTs
investigating the efﬁcacy of pharmacological interven-
tions in HFpEF and have, for the ﬁrst time, comprehen-
sively assessed the reporting quality of these publications.
We show a trend in improving reporting quality of HFpEF
RCTs over time and following updates to CONSORT
guidelines, though there remains a considerable variation
in reporting quality, with many important aspects relating
to trial methodology and results consistently under-
reported. The mean CONSORT 2010 score for HFpEF
RCTs is 55.4%, comparable to the ﬁndings from similar
contemporary studies in other ﬁelds of medicine and
surgery.13–17 We also identiﬁed a strong positive correl-
ation between the CONSORT score and metrics of
journal impact and author number.
Critical appraisal of the validity and generalisability of
study ﬁndings requires comprehensive reporting of clin-
ical trials, with discrepancies associated with variations in
effect estimate that may affect management decisions by
doctors and policymakers. Although several criteria were
well reported, we identiﬁed signiﬁcant deﬁciencies in
trial methodology and reporting of results. These have
impact on readers’ assessments of study quality and risk
of bias, and will reduce the quality and accuracy of
meta-analyses. Similar reviews have echoed these ﬁnd-
ings, highlighting particularly poor reporting of details
surrounding randomisation.2 14–18 Chen and Liu2
showed that the reporting of methodology in RCTs in a
high impact cardiology journal was inadequate, with
70% of studies reporting less than half of methodo-
logical items sufﬁciently, with randomisation and blind-
ing frequently affected.
The CONSORT 2010 score demonstrates positive cor-
relation with the year of publication, with articles pub-
lished after 2010 scoring more favourably than those
from earlier periods. The CONSORT update in 2010 is
likely to have generated increased awareness of the
importance of high reporting standards. A Cochrane
review in 2012 demonstrating superior reporting quality
of articles published by journals that endorse CONSORT
guidelines compared with those that did not, and
improvements after a journal’s endorsement of
CONSORT.19 Accordingly, almost 600 biomedical jour-
nals, including Open Heart, endorse CONSORT and
advise adherence from submitting authors.20
We demonstrate positive correlation between measures
of journal impact with CONSORT score. Although
authors will aim to submit the most thoroughly reported
studies to the most inﬂuential publishers, higher impact
factor journals have higher rejection rates and will there-
fore impose more rigorous presubmission checks and
review processes. Furthermore, better-reported studies
Figure 4 Individual study CONSORT 2010 score grouped by
latest CONSORT statement at the time of publication.
Individual study CONSORT 2010 score (open circles)
grouped by available CONSORT statement (1996, 2001 and
2010) at the time of study publication, with mean scores
during each period (filled circles).
Table 2 Effects of trial characteristics on CONSORT
score
Variable
Mean score
(SD) p Value
Treatment duration
<12 m (n=21) 53.1% (17.8%) NS
≥12 m (n=12) 59.4% (16.1%)
Participant number
<100 (n=16) 46.5% (13.5%) 0.011
≥100 (n=17) 63.7% (16.4%)
Primary end point result
Positive 57.5% (19.6%) NS
Negative 52.7% (15.5%)
Centres
Single centre (n=14) 48.0% (14.0%) NS
Multicentre (n=10) 57.3% (19.0%)
International
multicentre (n=9)
64.8% (16.2%)
Assignment
Parallel (n=5) 49.1% (20.1%) NS
Crossover (n=28) 56.5% (16.8%)
Funding/sponsor
National, charity,
academic (n=18)
56.5% (15.4%) NS
Pharmaceutical company,
industry (n=15)
59.2% (17.0%)
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may be more extensively cited, with a corresponding
positive inﬂuence on journal impact factor.
Significance of reporting quality in HFpEF clinical trials
As in all conditions with uncertain therapies, the
meta-analysis of pooled trial and registry data are
important in increasing our understanding of possible
treatments for HFpEF. High-quality meta-analysis
depends on comprehensive and accurate trial informa-
tion, with particular emphasis on the population, inter-
vention and outcome measures, and trial design.
Although there have been many recent meta-analyses of
speciﬁc drug classes in HFpEF,21–23 the last comprehen-
sive review for all drug therapies in HFpEF was pub-
lished in 2011 and identiﬁed no reduction in all-cause
mortality for drug classes, individually and combined.24
Since then, there have been a large number of
new trials—including at least 14 RCTs identiﬁed in this
study—some of which have evaluated novel treatments
and there is value in including these in an updated
review.25
Detailed reporting of study inclusion criteria and
participant demographics are particularly important in
HFpEF clinical trials. Trial inclusion criteria are heteroge-
neous and have changed as the understanding of HFpEF
as a disease syndrome has evolved.26 Combinations of
LVEF cut-offs, prior heart failure hospitalisation, clinical
features, the presence or absence of comorbidities, echo-
cardiographic and haemodynamic parameters, and natri-
uretic peptide levels are being used as inclusion criteria.
In a recent analysis comparing three major HFpEF trials
(the Digitalis Investigation Group-Preserved Ejection
Fraction (DIG-PEF), Candesartan in Heart Failure
Assessment of Reduction in Mortality and morbidity
(CHARM-Preserved) and Irbesartan in Heart Failure
with Preserved systolic function (I-PRESERVE)), the
authors found that the I-PRESERVE study population was
most representative of HFpEF patients in the community,
possibly attributable to its comparatively stringent inclu-
sion criteria.27 Although strict inclusion criteria is likely
to reduce the recruitment of patients with LV systolic dys-
function, exclusion of signiﬁcant comorbidities may
result in a non-representative study population and
reduce the applicability of results to real-life settings.
Analysing the effects that patient selection criteria have
on published trial outcomes will be important in optimis-
ing future trial design.
The pathophysiological role of non-cardiac comorbid-
ities in patients with HFpEF is becoming well charac-
terised and better understood.28 29 HFpEF populations
demonstrate a high prevalence of pulmonary disease, dia-
betes mellitus and cardiometabolic disorders, anaemia,
chronic kidney disease (CKD) and obesity30–32 and are
independently associated with poor outcomes.33–36 The
distribution of such comorbidities in clinical trials is likely
to inﬂuence results, and indeed it has been argued that
the absence of positive outcomes may be related to inclu-
sion of non-HFpEF patients.37 Although patient
demographics were well reported (91% of all trials),
detailed description of important comorbidities was
much poorer: diabetes mellitus was reported in 70% of
trials, atrial ﬁbrillation in 52%, COPD in 18%, anaemia
in 9%, CKD in 9% and obesity in 6%. This shows that
while adherence to reporting standards is to be encour-
aged, it is important that salient information of particular
interest in HFpEF should be provided.
It is increasingly accepted that HFpEF is a heteroge-
neous condition with a range of disease phenotypes.
Using the novel approach of latent class analysis (LCA),
Kao et al38 used patients enrolled in the I-PRESERVE
study and identiﬁed a signiﬁcant positive response to
irbesartan compared with placebo in a group charac-
terised by high prevalence of obesity, diabetes mellitus
and hyperlipidaemia. Although LCA is one approach
that can identify subgroups with differing prognoses and
responses to treatments, this requires patient-level data
that can be challenging to access.39 Consequently, there
is strength in combining individual trial subgroup ana-
lyses using meta-analysis. This approach of investigating
treatment effects on different patient groups stratiﬁed by
variables will likely yield insight into which groups are
likely to respond to therapy. The ability and success of
this approach depends on the clear reporting of all pre-
speciﬁed analyses and primary and secondary outcomes,
including subgroup analyses and exploratory outcomes.
A review of heart failure disease-management pro-
grammes found that signiﬁcant and clinically important
differences within subgroups are not meta-analysed due
to a dearth of available reported data,40 a ﬁnding that is
likely to be true for HFpEF. Similarly, another group
undertaking meta-analysis of the effectiveness of
pharmacological treatments in patients with NYHA class
I or II symptoms were unable to do so due to poor
reporting and non-disclosure of data.39
Important aspects of HFpEF trial design can inﬂuence
outcomes and the investigators’ ability to detect differ-
ences.41 As demonstrated in the Perindopril in Elderly
People with Chronic Heart Failure (PEP-CHF) study, the
primary end point of all-cause mortality and unplanned
heart failure hospitalisation trended towards statistical
signiﬁcance at 12 months (HR 0.69, p=0.055). However,
these beneﬁcial effects were lost by the end of the trial
(HR 0.92, p=0.545). This was due to a signiﬁcant propor-
tion of patients in the placebo arm going onto open-
label ACEi, resulting in an eventual study power of just
35%. The CHARM-preserved trial generated neutral
results, though study-drug discontinuation for adverse
events or laboratory abnormalities was signiﬁcantly
higher in the treatment arm than in the placebo arm
(18% vs 14%, p=0.001). The use of a run-in period to
establish drug tolerance may reduce the differential
effects of study drug discontinuation. Although trial
results have been largely neutral, it cannot be conclu-
sively argued that perindopril, candesartan or other
HFpEF trial treatments are of no clinical beneﬁt, as trial
design and limitations can clearly affect the ability of
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studies to detect meaningful differences and must there-
fore be clearly reported.
Geographic variation in the rates of mortality and hos-
pitalisation in HFpEF clinical trials has been well
described.42 In the Treatment of Preserved Cardiac
Function with Aldosterone Antagonist Trial (TOPCAT),
the primary end point rate was far lower in Russia and
Georgia (unadjusted rate of 2.3 per 100 patient-years in
placebo group) than in the Americas (12.6 per 100
patient-years).43 Similar results were found for the
CHARM-Preserved and I-PRESERVE trials, with
unadjusted rates of mortality, and adjusted rates for hos-
pitalisation for heart failure greater in North America
compared with Eastern Europe and Russia.42 This vari-
ation is more speciﬁc for trials of HFpEF rather than
trials of HFrEF and may reﬂect the logistical challenges
and disparate criteria for diagnosing HFpEF, or differing
provision of healthcare services available.42 Regional var-
iations in outcome rates are an important consideration
in international, multicentre RCTs, with clear reporting
of trial centre locations and number of patients enrolled,
event rates by regional area and subgroup analysis by
region all important in understanding the inﬂuence that
geographical variation has on treatment outcomes.
Study limitations
One limitation of our study methods is that the outcome
measure, CONSORT 2010 score, requires subjective
assessment. Publications from CONSORT provide good
guidance on this,1 and scoring was carried out blindly by
two assessors in this study. We showed a high degree of
interobserver agreement, comparable with other similar
published studies, with all discrepancies resolved by dis-
cussion. The use of ‘N/A’ as an additional qualiﬁer pro-
tects studies against falsely low scores, by only scoring
articles out of a relevant total. It must be emphasised that
a study’s CONSORT score does not reﬂect the quality of
the study or its risk of bias. Rather, high-quality reporting
is necessary for accurate meta-analysis, trial evaluation to
aid interpretation and implementation, and allows contri-
butions to the wider body of work. One argument against
the rigid use of CONSORTor its surrogate as a marker of
article reporting quality is that certain aspects may be
deemed to be unnecessary (eg, absolute risk difference
may be easily calculated from the individual event rates),
and indeed reviewers may ask for superﬂuous informa-
tion to be removed. In our study, we are unable to
discern whether failure to report a CONSORT item has
occurred due to authors, editors or reviewers.
CONCLUSIONS
The reporting quality of RCTs investigating the
impact of pharmacological interventions in HFpEF has
improved over time but remains suboptimal. We identi-
ﬁed a positive trend in the quality of reporting following
each revision of the CONSORT statement and demon-
strated correlation between the quality of study reporting
and journal impact factor. Encouragingly, reporting of
methodology and results increased signiﬁcantly after the
update of CONSORT in 2010. Although improvements
in adherence to CONSORT 2010 reporting criteria are
necessary, speciﬁc details related to inclusion criteria,
patient demographics, trial design and subgroup analysis
by important variables (participant demographics,
comorbidities and geographical variation) will provide
greater insight into treatment effects for HFpEF and
lend a basis on which future clinical trials be designed.
The treatment of HFpEF remains a substantial clinical
challenge and, given the relatively small number of dedi-
cated RCTs, transparent and complete reporting will
likely improve our understanding of the disease and its
treatments.
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